Skip to main content

Month: September 2024

Pharmaceutical Excipients Market to Witness 6.8% CAGR by 2031 | SkyQuest Technology

Pharmaceutical Excipients Market size was valued at USD 10.12 billion in 2023 to USD 17.13 billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031). Westford, USA, Sept. 26, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Pharmaceutical Excipients Market will attain the value of USD 17.13 Billion by 2031, with a CAGR of 6.8% during the forecast period (2024-2031). The increasing prevalence of chronic lifestyle diseases across the globe, coupled with huge investments by pharmaceutical companies in biopharmaceuticals, is expected to significantly impact the growth of the global market during the forecast period. Furthermore, the company is expected to have widespread adoption of pharmaceuticals in many developing countries promising expansion opportunities over time.  Browse in-depth TOC on ” Pharmaceutical...

Continue reading

Key Carbon & Marex Group Announce Carbon Financing and Investment

VANCOUVER, British Columbia and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Key Carbon and Marex Group Plc (“Marex”) today announce a partnership whereby Marex will take a minority stake in Key Carbon and provide financing for carefully-sourced offset projects. Key Carbon sources and finances carbon credit projects and provides ongoing governance, monitoring and operational support to ensure its projects are held to the highest quality and integrity standards. The funding from Marex will predominantly be used to help finance the production and distribution of low-emission, affordable cookstoves within Africa through the project developer Global Cookstoves, Key Carbon’s joint venture with BURN Manufacturing (“BURN”). To date, Key Carbon has provided US$45 million in funding to Global Cookstoves to expand the roll out of critical projects...

Continue reading

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol’s prescribing information NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery. “The commercial launch of Clobetasol represents a significant milestone for our company, and as the first new ophthalmic steroid to be approved in more than 15 years, a meaningful advancement in the field of ocular surgery,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “With its efficacy and safety profile, convenient twice-a-day dosing regimen, and streamlined...

Continue reading

Virtu Financial Congratulates Women in Finance Award Recipients Leah Goldsberry and Trish McMenamin

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (Nasdaq:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, is proud to announce that Trish McMenamin, Chief Compliance Officer, and Leah Goldsberry, EMEA Head of Analytics Client Coverage, have both been recognized at Markets Media’s European Women in Finance Awards. Trish McMenamin received the Excellence in Legal and Compliance award for her leadership in transforming Virtu’s Dublin-based regulatory program and her collaboration efforts across the global platform and global teams. With over a decade of experience, Trish has consistently demonstrated integrity and a commitment to compliance excellence. Leah Goldsberry was awarded...

Continue reading

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a webinar to discuss data from the Phase 1 study of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson’s disease, recently presented in a late-breaker at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS). The Company will also discuss the design of a planned Phase 1b trial of GT-02287 in Parkinson’s...

Continue reading

Shock Top’s Bold New Hard Iced LiiT Tea is Here

LiiT Hard Iced Tea is Now Available Nationwide in 19.2-ounce Cans PORTLAND, Ore., Sept. 26, 2024 (GLOBE NEWSWIRE) — The Shock Top Company, a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is excited to introduce its latest innovation: Shock Top LiiT Hard Iced Tea. With a robust 9% alcohol content by volume, this hard iced tea is designed to keep the good times rolling, even as the days get shorter. This isn’t your grandma’s iced tea. Shock Top’s LiiT packs a punch with bold flavors and a refreshing twist that’s perfect for those who aren’t quite ready to let go of summer. Think of it as your new go-to companion for all things fall – from tailgates to bonfires – LiiT is the beverage that’ll keep your spirits high as temperatures drop. Launching nationwide today, Shock Top LiiT Hard Iced Tea will be available in...

Continue reading

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

– Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer – – Chad Cowan, Ph.D., cell therapy pioneer, founder, and former CEO of Clade Therapeutics, appointed as Chief Scientific Officer – – Hy Levitsky, M.D., President of Research and Development, to transition to an advisor to Century – PHILADELPHIA, Sept. 26, 2024 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced the appointments of Morgan Conn, Ph.D., as Chief Financial Officer and Chad Cowan, Ph.D., as Chief Scientific Officer. The appointments are effective October...

Continue reading

White Gold Corp. Encounters Gold in Encouraging Host Rocks of Altered and Mineralized Intrusives in Surface Rock Sampling over 1.25km on the Newly Discovered 2.2km Chris Creek Target on the QV Property

Figure 1 – QV Property Location MapFigure 1 – QV Property Location MapFigure 2 – Chris Creek 2024 Rock Sampling and Drilling RegionFigure 2 – Chris Creek 2024 Rock Sampling and Drilling RegionFigure 3 – Chris Creek Trend Soil Anomaly (Au, Mo, Hg, Te, Sb, As)Figure 3 – Chris Creek Trend Soil Anomaly (Au, Mo, Hg, Te, Sb, As)Figure 4 – QV Property OverviewFigure 4 – QV Property OverviewFigure 5 – ChrisCreek-VG-GS ComparisonFigure 5 – ChrisCreek-VG-GS ComparisonTORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company”) is pleased to announce that surface rock sampling has encountered gold with associated anomalous silver and tellurium in altered and mineralized intrusive rocks...

Continue reading

Surge Copper Completes 2024 Field Program and Provides Corporate Update

Vancouver, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to announce the successful completion of its 2024 field program at its 100%-owned Berg and Ootsa copper-molybdenum-precious metals projects located in central British Columbia. Field crews have now been demobilized, and with the conclusion of physical operations, the Company is ramping down associated expenditures as it transitions into the data analysis and reporting phase. 2024 Field Program HighlightsCompleted a total of 13 diamond drill holes for 5,054 metres:At the Berg Project, 10 holes were drilled for a total of 3,707 metres within the main Berg deposit, with an additional 450-metre hole testing the Berg SW exploration target. At the Ootsa Project, two...

Continue reading

Xtract One Technologies Teams Up with UBS Arena, Home of the NHL’s New York Islanders

SmartGateway Systems will be Deployed to Protect Patrons and Elevate their Ingress Experience TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that its SmartGateway screening solution was selected to secure UBS Arena in New York. This contract is enabled through the Company’s partnership with Oak View Group (OVG), a global sports and entertainment company. UBS Arena, an 18,000-seat capacity venue located in New York’s historic Belmont Park, is home to the National Hockey League’s (NHL) New York Islanders. Xtract One will provide fast and frictionless fan screening to optimize UBS Arena’s patron experience...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.